Crystagen

Crystagen is a synthetic tripeptide bioregulator with the reported amino-acid sequence Glu-Asp-Pro (EDP), developed within the Khavinson short-peptide bioregulation program at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the same family of short organ-directed peptides as Vilon (Lys-Glu), Thymogen (Glu-Trp) and Epitalon (Ala-Glu-Asp-Gly), and is classified in that literature as an immune bioregulator. The molecule is strongly anionic at neutral pH — the glutamic-acid and aspartic-acid residues each carry a carboxylate side chain — while the C-terminal proline imposes backbone rigidity through its pyrrolidine ring. Published work on Crystagen is largely Russian-language and preclinical, using it as a molecular probe in spleen, thymocyte and lymphoid-tissue models of immune aging. This product supplies the defined-sequence synthetic tripeptide; it should not be confused with the related Glu-Asp-X bioregulators (Glu-Asp-Gly, Glu-Asp-Arg, Glu-Asp-Ala) that differ only at the third residue. This material is supplied for research use only and is not for human consumption.

The Khavinson bioregulation hypothesis holds that short peptides of this class penetrate the cytoplasmic and nuclear membranes and interact directly with DNA, so that a single tripeptide can influence the expression of multiple genes. Molecular-docking work on the family placed EDP among peptides that bind a specific short DNA motif, positioning sequence-selective peptide–DNA association as the proposed mechanistic basis for its bioregulatory activity rather than a classical cell-surface receptor. In cellular immunology models, Crystagen has been reported to act on the B-lymphocyte compartment of aging spleen tissue without measurably altering proliferation or apoptosis in that tissue, distinguishing its reported profile from Vilon and Thymogen, which were examined in parallel. Comparative organotypic work on Glu-Asp-X tripeptides indicates that activity is sensitive to the identity of the third residue, which is why structure-activity comparison across the series is a common experimental design. All of these mechanisms remain hypotheses under investigation in laboratory research models.

Immunoprotective Profile in Aging Spleen

Chervyakova et al. (2014) compared the short peptides Vilon, Thymogen, Crystagen and R-1 in spleen tissue during aging and reported that each produced a distinct immunoprotective profile. Crystagen was reported to activate the B-cell arm of the immune system, but — unlike Vilon and Thymogen — was not associated with cell-renewal effects in the aging spleen [1].

Peptide-DNA Binding and Gene Regulation

Khavinson, Lin’kova and Tarnovskaya (2016) built spatial models of DNA-peptide complexes for 19 short peptides by docking, proposing that short peptides cross the cytoplasmic and nuclear membranes and bind DNA directly. EDP was reported to bind the same short DNA motif as the dipeptide KE, supporting sequence-selective DNA association as a candidate mechanism for this peptide class [2].

Comparative Tripeptide Structure-Activity Work

Voicekhovskaya et al. (2012) examined a panel of bioregulatory tripeptides — including T-36 (Glu-Asp-Pro) alongside Glu-Asp-Ala, Glu-Asp-Arg, Glu-Asp-Gly and Lys-Glu-Asp — in organotypic cultures of young and old rat skin, tracking proliferation and p53 expression. The differing responses across a series that varies at a single residue illustrate why Glu-Asp-X peptides are studied as a comparative set [3].